We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we'll assume that you are happy to receive all cookies on the medicines.ie website. Find out more

Meda Health Sales

Unit 34/35, Block A, Dunboyne Business Park, Dunboyne, Co. Meath, Dublin, Ireland
Telephone: 00 353 18026624
Fax: 00 353 18026629
Medical Information Direct Line: 00 353 1 802 6627
Medical Information e-mail: medinfo@meda.ie
Medical Information Facsimile: 00 353 1 802 6629

Summary of Product Characteristics last updated on medicines.ie: 10/07/2015
SPC Efudix 5% Cream

Go to top of the page

Efudix 5% w/w Cream.

Go to top of the page

Efudix cream contains:

Active substance:

5% w/w




stearyl alcohol


propylene glycol (E1520)


methyl parahydroxybenzoate (E218)


propyl parahydroxybenzoate (E216)

For a full list of excipients, see section 6.1.

Go to top of the page


Smooth, white, opaque cream.

Go to top of the page

Go to top of the page
4.1 Therapeutic indications

Efudix is used for the topical treatment of superficial pre-malignant and malignant skin lesions; keratoses including senile, actinic and arsenic forms; keratoacanthoma, Bowen's disease, superficial basal-cell carcinoma. Deep, penetrating or nodular basal cell and squamous cell carcinomas do not usually respond to Efudix therapy. It should be used only as a palliative therapy in such cases where no other form of treatment is possible.

Go to top of the page
4.2 Posology and method of administration

Adults, including the elderly:

The cream should be applied thinly once or twice daily to the lesion. An occlusive dressing should preferably be used with malignant lesions. The usual treatment course is 3 to 4 weeks, but this may be prolonged if required.

Children: not recommended.

Go to top of the page
4.3 Contraindications

• Pregnancy or lactation

• Known hypersensitivity to Efudix or parabens.

Go to top of the page
4.4 Special warnings and precautions for use

• Care should be taken to avoid contact with the eyes or mucous membranes and hands should be washed thoroughly after applying the cream.

• An area in excess of 500 cm2 should not be treated at one time.

• If the product is used excessively or the area of application is extensive and ulceration is present, absorption may occur.

• The pattern of normal therapeutic response to Efudix follows a sequence of erythema, vesiculation, erosion, ulceration and necrosis followed by epithelialisation, without damaging normal skin. Therefore, the appearance of the lesions may initially be worse prior to resolution.

• This product should be used under specialist medical direction.

• Patients should not treat further lesions similar to those for which the product was originally recommended without seeking further medical advice.

• The excipients stearyl alcohol and propylene glycol may cause local skin irritations (e.g. contact dermatitis); the excipients methyl parahydroxybenzoate and propyl parahydroxybenzoate may cause allergic reactions (possibly delayed).

Go to top of the page
4.5 Interaction with other medicinal products and other forms of interaction

No significant drug interactions with Efudix have been reported.

Go to top of the page
4.6 Pregnancy and lactation

Use during pregnancy or in lactation in women breast feeding infants is not recommended. Animal studies indicate that there is a teratogenic effect and there is no evidence of safety in human pregnancy.

Go to top of the page
4.7 Effects on ability to drive and use machines

None known.

Go to top of the page
4.8 Undesirable effects

Efudix is well tolerated. Transient erythema may occur in healthy skin surrounding the area being treated. Pre-existing subclinical lesions may become apparent. Exposure to sunlight may increase the intensity of the reaction. Dermatitis, allergic skin reactions and, rarely, erythema multiforma has been reported (see 4.4 Special Warnings and Precautions for Use).

Percutaneous absorption of fluorouracil should not lead to clinically significant systemic toxicity when Efudix is administered as directed. However, this possibility should be borne in mind if the product is used excessively, especially on ulcerated or broken skin.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via HPRA Pharmacovigilance, Earlsfort Terrace, IRL – Dublin 2; Tel: +353 1 6764971; Fax: +353 1 6762517. Website: www.hpra.ie; E-mail: medsafety@hpra.ie.

Go to top of the page
4.9 Overdose

If Efudix is accidentally ingested, signs of fluorouracil overdosage may include nausea, vomiting and diarrhoea. Stomatitis and blood dyscrasias may occur in severe cases. Appropriate measures should be taken for the prevention of systemic infection and daily white cell counts should be performed.

Go to top of the page

Go to top of the page
5.1 Pharmacodynamic properties

Efudix is a topical cytostatic preparation which exerts a beneficial therapeutic effect on neoplastic and pre-neoplastic skin lesions without damaging normal skin. The pattern of response follows this sequence, erythema, vesiculation, erosion, ulceration, necrosis and epithelisation. The active ingredient fluorouacil is a fluorinated analogue or uracil, a component of RNA. Fluorouracil interferes with DNA and RNA synthesis at the nucleotide level.

Go to top of the page
5.2 Pharmacokinetic properties

Animal studies have shown that after topical application of fluorouracil, less than 10% is systemically absorbed. This may be metabolised by catabolic or anabolic routes which are similar to that of endogenous uracil.

Go to top of the page
5.3 Preclinical safety data

No new data are presented

Go to top of the page

Go to top of the page
6.1 List of excipient(s)

Stearyl alcohol

White soft paraffin

Polysorbate 60

Propylene glycol (E1520)

Methyl parahydroxybenzoate (E218)

Propyl paradroxybenzoate (E216)

Purified water

Go to top of the page
6.2 Incompatibilities

Not applicable.

Go to top of the page
6.3 Shelf life

5 years.

Shelf life after first opening the immediate packaging: 28 days for the 5g tube, 90 days for the 20g and 40g tubes

Go to top of the page
6.4 Special precautions for storage

Do not store above 30°C.

Go to top of the page
6.5 Nature and contents of container

Efudix cream is packed in 40g, 20g and 5g aluminium membrane-sealed tubes, coated inside with an epoxy phenolic resin derivative lacquer. The tube is closed with a polypropylene PP membrane piercing cap.

Not all pack sizes may be marketed.

Go to top of the page
6.6 Special precautions for disposal and other handling

Efudix is for topical use only and care should be taken to avoid contact with mucous membranes or the eyes. The hands should be washed carefully after applying the cream.

Go to top of the page

Meda Health Sales Ireland Limited,

Unit 34/35, Block A,

Dunboyne Business Park,

Dunboyne, Co. Meath,


Go to top of the page

PA 1332/32/1

Go to top of the page

Date of first authorisation: 1st April 1979

Date of last renewal: 01st April 2009

Go to top of the page

June 2015

Link to this document from your website:

Document Links

  Link to this page
  View all medicines
from this company
Print this page
View document history
Bookmark and Share

Active Ingredients